Ontario Institute for Cancer Research, Toronto, Canada.
Department of Radiation Oncology, Duke Cancer Institute, Durham, North Carolina, USA.
Eur Urol Focus. 2019 Mar;5(2):159-161. doi: 10.1016/j.euf.2018.12.009. Epub 2019 Jan 12.
Advanced prostate cancer patients can present with both widely metastatic or oligometastatic disease. Accumulating clinical evidence suggests that patients with oligometastatic disease have improved clinical responses from metastasis-directed therapy. This suggests that tumours that give rise to the oligometastatic state are distinct biologically and genetically from those that induce widely metastatic lesions. Detailed genomic analysis of the oligometastatic state will identify the molecular events that distinguish localised from metastatic disease, defining the molecular signatures of curability. The GAP6 consortium is well poised to address this question. PATIENT SUMMARY: In this report, we have reviewed the evidence that prostate cancer patients with only a small number of distant tumour deposits have cancers that are driven by genetic and biological changes, which are distinct from those tumours that readily spread to many distant sites. So far, the evidence is not clear cut; however, in-depth studies to answer this question are underway.
晚期前列腺癌患者可能同时患有广泛转移或寡转移疾病。越来越多的临床证据表明，寡转移疾病患者的转移导向治疗有更好的临床反应。这表明，导致寡转移状态的肿瘤在生物学和遗传学上与诱导广泛转移病变的肿瘤不同。对寡转移状态的详细基因组分析将确定区分局限性和转移性疾病的分子事件，确定可治愈性的分子特征。GAP6 联盟非常适合解决这个问题。患者总结：在本报告中，我们回顾了证据，表明只有少数远处肿瘤沉积物的前列腺癌患者的癌症是由遗传和生物学变化驱动的，这些变化与那些容易扩散到许多远处部位的肿瘤不同。到目前为止，证据还不是很明确；然而，正在进行深入的研究来回答这个问题。
